NovaBay Pharmaceuticals, Inc. - FORM 10-K - EX-23.1 - CONSENT OF ODENBERG, ULLAKKO, MURANISHI & CO. LLP - March 10, 2011

Attached files

file filename
10-K - ANNUAL REPORT - NovaBay Pharmaceuticals, Inc.nova_10k-123110.htm
EX-23.2 - CONSENT OF DAVIDSON & CO, LLP - NovaBay Pharmaceuticals, Inc.ex23-2.htm
EX-31.2 - CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 - NovaBay Pharmaceuticals, Inc.ex31-2.htm
EX-31.1 - CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 - NovaBay Pharmaceuticals, Inc.ex31-1.htm
EX-23.1 - CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 - NovaBay Pharmaceuticals, Inc.ex32-1.htm
EX-10.24 - AMENDMENT NO. 2 TO THE COLLABORATION AND LICENSE AGREEMENT, DATED AS OF DECEMBER 2, 2010, BETWEEN THE COMPANY AND GALDERMA S.A. - NovaBay Pharmaceuticals, Inc.ex10-24.htm
EX-10.25 - AMENDMENT NO. 1 TO THE COLLABORATION AND LICENSE AGREEMENT DATED NOVEMBER 18, 2010 BY AND BETWEEN THE COMPANY AND ALCON MANUFACTURING, LTD. - NovaBay Pharmaceuticals, Inc.ex10-25.htm
EX-23.2 - CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 - NovaBay Pharmaceuticals, Inc.ex32-2.htm
Exhibit 23.1

 
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 
We consent to the incorporation by reference in Registration Statements on S-8 (333-147334, 333-157041, 333-164469, and 333-171981) and on Form S-3 (333-159917) of our report dated March 7, 2011, with respect to the consolidated financial statements of NovaBay Pharmaceuticals, Inc. included in its Annual Report on Form 10-K for the year ended December 31, 2010.
 
 
 
/S/ Odenberg, Ullakko, Muranishi & Co. LLP
San Francisco, CA
March 7, 2011

NovaBay Pharmaceuticals, Inc. Reports